HOWL
Werewolf Therapeutics, Inc.
Key Financials
Net Income
$-60822000
↑ 13.7%
EPS (Diluted)
$-1.33
↑ 18.4%
Operating Income
$-60677000
↑ 17.6%
Shareholders' Equity
$24.8M
↓ 66.2%
Total Liabilities
$44.6M
↓ 16.7%
Cash & Equivalents
$57.0M
↓ 48.6%
Long-term Debt
$32.1M
0.0%
Total Assets
$69.4M
↓ 45.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-K | 3/27/2026 | View on SEC |
| 8-K | 3/27/2026 | View on SEC |
| 3 | 3/13/2026 | View on SEC |
| 8-K | 2/24/2026 | View on SEC |
| 8-K | 2/13/2026 | View on SEC |
| SCHEDULE 13G/A | 2/11/2026 | View on SEC |
| 8-K | 2/6/2026 | View on SEC |
| 4 | 1/20/2026 | View on SEC |
| SCHEDULE 13D/A | 1/16/2026 | View on SEC |
| 4 | 1/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | HOWL |
| Company Name | Werewolf Therapeutics, Inc. |
| CIK | 1785530 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-952-0555 |